Interestingly, TRP agonists also showed antitumor effects, with the TRPV4 agonist GSK1016790A reducing breast cancer cell viability, and endogenous overexpression of TRPV4 was evident in vitro, leading to reduced tumor growth in vivo. Here, TRPV4 is linked to breast carcinoma.